ATAI News and Press, ATAI Life Sciences N.V.

2024-07-03 09:48:30 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Psychedelics could be a game-changer in treating mental health issues. All of which could help create big opportunities for top psychedelic stocks. According to the American Psychologi...

NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s manage...

--News Direct-- Atai Life Sciences co-founder and co-CEO Florian Brand discussed initial results from Beckley Psytech’s phase 1 trial of its patent-protected psilocin ELE-101 in patients with major depressive disorder. Brand explained that ELE-101 is an intravenous (IV) formula...

About a week ago, an advisory committee to the U.S. Food and Drug Administration (FDA) rejected evidence supporting the approval of MDMA as an alternative treatment for post-traumatic stress disorder (PTSD). This is a deflating moment for many in psychedelic research who have, for years, conduc...

ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hours. The Phase 2a part of the study will evaluate the safety, tolerability, subj...

Therapeutic interest in psychedelics has grown as researchers learn more about the potential of these substances to manage the symptoms of different mental-health conditions and improve the well-being of individuals. Now, new research has determined that psychedelic experiences can cause a decr...

2024-06-05 14:37:06 ET Summary Shares of psychedelic medicine developers fall after the FDA panel votes against approving MDMA for PTSD treatment. U.S. private sector job growth falls short of expectations, raising concerns about the labor market. Wells Fargo's Chris Harvey co...

2024-06-05 07:17:36 ET More on ATAI, COMPASS Pathways, etc. ATAI: Enormous Potential Upside But No Clarity Yet Psychedelics Closer To Commercialization; Compass Far And Away The Leader COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript Biggest stock...

2024-06-04 17:32:04 ET More on psychedelic drug companies ATAI: Enormous Potential Upside But No Clarity Yet Psychedelics Closer To Commercialization; Compass Far And Away The Leader COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript Psychedelic sto...

A new study looking into the effect of psychedelics on individuals who stutter has determined that the drugs may have some benefits. The documented effects of classic psychedelic drugs such as LSD or psilocybin mushrooms are plenty, with researchers noting that their positive effects can be a r...